# Regional Health Properties, Inc. (RHEP)

> Source: Nexqual · https://nexqual.com/RHEP · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Regional Health Properties, Inc. (RHEP), nexqual.com/RHEP" · informational, not investment advice.

**Price:** USD 1 (-2.91% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 1.03 · day 1.02–1.02 · 52w 0.91–1.55 · market cap $3.9M · OQB

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $81.5M, net income $4.1M (5.0% margin), free cash flow -$3.9M (SEC filings).
- Valuation: P/E 1.0x (avg 0.0x at the last 1 fiscal year-ends), EV/EBITDA 10.4x, net debt $40.9M.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $6K; 1 not under a Rule 10b5-1 plan ($6K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $77K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -28.1% vs S&P 500 +13.4%; 5Y -84.7% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $26.7M | $35.9M | $17.2M | $18.3M | $53.2M | $81.5M |
| Gross profit | — | — | — | — | $46.2M | — |
| Operating income | $2.5M | -$6.8M | -$821K | $161K | $1.7M | $1.6M |
| Net income | -$1.2M | -$6.9M | -$3.9M | -$3.2M | $3.4M | $4.1M |
| EPS (diluted) | -$5.87 | -$8.93 | $21.05 | -$1.73 | $1.09 | — |
| Free cash flow | $4.8M | -$3.9M | $2.8M | $1.4M | -$3.1M | -$3.9M |
| Gross margin | — | — | — | — | 86.9% | — |
| Operating margin | 9.5% | -19.0% | -4.8% | 0.9% | 3.1% | 1.9% |
| Net margin | -4.4% | -19.1% | -22.7% | -17.6% | 6.3% | 5.0% |
| Revenue growth | +51.8% | +34.6% | -52.2% | +6.8% | +189.9% | — |
| Cash + short-term investments | $6.8M | $800K | $1.0M | $582K | $3.0M | — |
| Total debt | $52.9M | $52.2M | $50.7M | $49.7M | $43.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 1.0x · P/S 0.1x · EV/EBITDA 10.4x · EV/Sales 0.6x · FCF yield -100.36% · Earnings yield 103.68% · Net debt $40.9M · EV $44.8M
P/E at fiscal year-ends: Dec 2025 0.0x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-05…2026-06-15 | Radoff Bradley Louis |  | 5,100 | $6K | 1.5% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $77K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-27…2026-06-05 | Morrison Brent | CEO and President | 20,000 | $28K | 1.38 | Too little history (no open-market trades in 2024) |
| 2026-05-20…2026-05-21 | Morrison Brent | CEO and President | 17,000 | $30K | 1.79 | Too little history (no open-market trades in 2024) |
| 2026-04-13…2026-04-29 | Radoff Bradley Louis |  | 14,420 | $19K | 1.33 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -28.1% | -84.7% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -28.1% | -31.3% |
| Volatility (annualized) | 67.8% | 86.5% |
| Max drawdown | -36.7% (Dec 2025→Sep 2026) | -87.0% (Nov 2021→Sep 2026) |

## Peers (Medical Care Facilities)
INNV (InnovAge Holding Corp.) USD 9.55 +0.32% · USPH (U.S. Physical Therapy, Inc.) USD 88.53 -0.23% · NUTX (Nutex Health Inc.) USD 209.59 +1.70% · PNTG (The Pennant Group, Inc.) USD 41.88 -0.83% · AGL (agilon health, inc.) USD 89.71 -0.64% · CMPS (COMPASS Pathways Plc - American) USD 11.18 -3.87%

## More
Full page: https://nexqual.com/RHEP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Healthcare Services | $14.0M | 57.3% | +59.6% | $706,000 | 5.0% |
| Pharmacy Service | $9.7M | 39.5% | — | -$142,000 | -1.5% |
| Real Estate Services | $786,000 | 3.2% | -38.7% | -$780,000 | -99.2% |
| Total revenue | $24.4M | 100% | — | -$216,000 | -0.9% |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Health Care Patient Service | $14.0M | 57.3% | +59.6% |
| Pharmacy Revenues | $9.6M | 39.4% | — |
| Rental Revenue | $801,000 | 3.3% | -37.6% |
| Total revenue | $24.4M | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |